Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 3 matches for

Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.

A graph showing the growth of finance raised by UK-based biotech companies from 2016-2020. 2016 - IPO £105M, Ventre Capital £681M, All other public financings £344M, Total £1,130M. 2017 - IPO £234M, Ventre Capital £515M, All other public financings £452M, Total £1,201M. 2018 - IPO £432M, Ventre Capital £1,113M, All other public financings £658M, Total £2,203M. 2019 - IPO £64M, Ventre Capital £679M, All other public financings £596M, Total £1,339M. 2020 - IPO £244M, Ventre Capital £1,389M, All other public financings £1,176M, Total £2,809M.
Source: UK BioIndustry Association, 2021

BioEscalator Bulletin - Spring 2025

Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Spring 2025 edition of the BioEscalator Bulletin.

BioEscalator Bulletin – Annual Review 2023/24 launched

The BioEscalator is delighted to have launched its inaugural Annual Review, ‘Driving innovation, advancing human health ’. It provides for the first time a discussion of our achievements in 2023/24, plus the milestones from our initial five years of operation.

BioEscalator Bulletin - Winter 2024

Similar stories